Zachary Jennifer's most recent trade in Regenxbio Inc was a trade of 46,600 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on May 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2026 | 46,600 | 46,600 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2026 | 9,807 | 31,871 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 35,312 | 35,312 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 12,064 | 12,064 | - | - | Restricted Stock Unit | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2026 | 2,951 | 5,903 | - | - | Restricted Stock Unit | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 110.03 per share. | 29 Apr 2026 | 2,951 | 72,351 (0%) | 0% | 110.0 | 324,699 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.03 per share. | 29 Apr 2026 | 1,454 | 70,897 (0%) | 0% | 110.0 | 159,984 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 56,792 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 119.15 per share. | 09 Feb 2026 | 56,792 | 68,915 (0%) | 0% | 119.2 | 6,766,892 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.15 per share. | 09 Feb 2026 | 56,792 | 125,707 (0%) | 0% | 119.2 | 6,766,892 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 119.15 per share. | 09 Feb 2026 | 38,835 | 68,915 (0%) | 0% | 119.2 | 4,627,276 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.15 per share. | 09 Feb 2026 | 38,835 | 107,750 (0%) | 0% | 119.2 | 4,627,276 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 38,835 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.15 per share. | 09 Feb 2026 | 25,946 | 94,861 (0%) | 0% | 119.2 | 3,091,523 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 25,946 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 119.15 per share. | 09 Feb 2026 | 25,946 | 68,915 (0%) | 0% | 119.2 | 3,091,523 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 107.40 per share. | 26 Jan 2026 | 11,583 | 68,915 (0%) | 0% | 107.4 | 1,244,014 | Common Stock |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 39,815 | 39,815 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 7,768 | 22,064 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 40,301 | 40,301 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 8,854 | 8,854 | - | - | Restricted Stock Unit | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 25,423 | 55,285 (0%) | 0% | 97.9 | 2,489,929 | Common Stock |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 24,454 | 24,454 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 4,790 | 14,296 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 35,156 | 35,156 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 126.97 per share. | 02 Feb 2024 | 49,499 | 29,057 (0%) | 0% | 127.0 | 6,284,779 | Common Stock |
| Merck & Company | Zachary Jennifer | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.10 per share. | 02 Feb 2024 | 19,417 | 78,556 (0%) | 0% | 87.1 | 1,691,221 | Common Stock |
| Merck & Company | Zachary Jennifer | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 19,417 | 38,835 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Zachary Jennifer | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 119.43 per share. | 22 Jan 2024 | 23,298 | 59,139 (0%) | 0% | 119.4 | 2,782,480 | Common Stock |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 17,892 | 17,892 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 3,486 | 9,506 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 117.59 per share. | 04 May 2023 | 19,141 | 35,127 (0%) | 0% | 117.6 | 2,250,834 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 41,494 | 41,494 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 103.17 per share. | 03 Feb 2023 | 75,436 | 53,919 (0%) | 0% | 103.2 | 7,782,762 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 75,436 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.04 per share. | 03 Feb 2023 | 75,436 | 129,355 (0%) | 0% | 56.0 | 4,227,433 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 109.88 per share. | 23 Jan 2023 | 15,631 | 53,919 (0%) | 0% | 109.9 | 1,717,534 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 99.07 per share. | 28 Oct 2022 | 99,768 | 103,527 (0%) | 0% | 99.1 | 9,884,016 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 68,367 | 123,015 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 68,367 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 99.85 per share. | 28 Oct 2022 | 65,487 | 38,040 (0%) | 0% | 99.9 | 6,538,877 | Common Stock |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 51,884 | 174,899 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 51,884 | 25,946 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 28,396 | 203,295 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 28,396 | 56,792 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 29,739 | 29,739 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 6,020 | 6,020 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 58,252 | 58,252 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 18,420 | 53,419 (0%) | 0% | 73.5 | 1,354,054 | Common Stock |